Ann: Finance Facility and Creditor Restructure Update, page-36

I just have three questions to add as I think the above covers most.
I'd like a time line for the watch and maybe some input on FDA approval?
Are they still pursuing general clearance for the pulse for mass market distribution.
What is the board doing to protect share holders interest after the raise debacle and although I appreciate Craig stumping up cash, I am concerned about the switch from participation in the raise to a convertible note. I Like to know the boards path to protecting shareholders during this phase.